Multi-component oncofertility care intervention for Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Pioneers Medical Health District, Brawley, CA
Breast Cancer+4 More
Multi-component oncofertility care intervention - Behavioral
Eligibility
18 - 65
Female
What conditions do you have?
Select

Study Summary

The purpose of this study is to evaluate the effectiveness of a multi-component intervention to improve young breast cancer survivors' engagement in goal-concordant oncofertility care, concurrently with observing and gathering information on how the intervention is implemented. The investigators hypothesize that implementation of the intervention will result in increased young breast cancer survivors' engagement in goal-concordant oncofertility care.

Eligible Conditions

  • Breast Cancer
  • Menopausal Symptoms
  • Contraception
  • Fertility

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 12 weeks after oncology visit

Week 12
Medical record review of engagement in goal-concordant oncofertility care

Trial Safety

Trial Design

2 Treatment Groups

Usual Care
1 of 2
Multi-component oncofertility care intervention
1 of 2
Active Control
Experimental Treatment

135 Total Participants · 2 Treatment Groups

Primary Treatment: Multi-component oncofertility care intervention · No Placebo Group · N/A

Multi-component oncofertility care intervention
Behavioral
Experimental Group · 1 Intervention: Multi-component oncofertility care intervention · Intervention Types: Behavioral
Usual CareNoIntervention Group · 1 Intervention: Usual Care · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks after oncology visit

Trial Background

Prof. Hui-Chun Irene Su, Professor
Principal Investigator
University of California, San Diego
Closest Location: Pioneers Medical Health District · Brawley, CA
N/AFirst Recorded Clinical Trial
1 TrialsResearching Breast Cancer
0 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · Female Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have primary language English or Spanish.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.